Antibody against secreted n-terminal peptide of gpc3 present in blood or c-terminal peptide of gpc3
CA 2497744 C · Owner: Nakano, Kiyotaka · Inventors: Nakano, Kiyotaka; Tokita, Susumu; Aburatani, Hiroyuki
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed is an antibody against a secreted form of GPC3 capable of detecting a secreted form of glypican 3 (GPC3) in a test sample. It is possible to determine whether a subject suffers from cancer, in particular hepatoma. Also disclosed is an antibody against GPC as well as a cell disrupting agent and an anti-cancer agent comprising the same which can disrupt, cells, in particular cancer cells.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 4, 2003 and granted March 12, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 4, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 4, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.